Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This study is open to people with idiopathic pulmonary fibrosis (IPF) . They can only take part if they have completed treatment in a previous study with a medicine called HSK44459. The primary object of this study is to find out how well people with idiopathic pulmonary fibrosis (IPF) tolerate long- term treatment with HSK44459.

NCT Number	NCT07019090
Lead Sponsor	Haisco Pharmaceutical Group Co., Ltd.
Conditions	Idiopathic Pulmonary Fibrosis (IPF)
Enrollment	120 participants
Start Date	2025-06-27
Primary Completion	2026-10-31 (estimated)
Study Completion	2027-01-19 (estimated)
Updated on ClinicalTrials.gov	2025-06-13